Pricing Your Healthcare Product

Healthcare product pricing fails in a distinctive way: companies build a product, estimate a cost to produce it, add a margin, and call that a price. Then they discover that nobody in healthcare buys on cost-plus logic. Payers evaluate products against clinical alternatives. Hospital systems evaluate them against departmental budgets and margin contribution. Employers evaluate them against total cost of care for their workforce. Each of these buyers is asking a fundamentally different question, and a price that answers one question well can be entirely wrong for the others.

Value-based pricing in healthcare means anchoring price to the economic and clinical benefit the product generates, not to what it costs to make. The classic framework is cost-effectiveness analysis: what does this product cost per unit of health outcome produced, relative to the current standard of care? The benchmark most commonly used is cost per quality-adjusted life year, or QALY — a measure that combines survival and quality of life into a single unit. If your product produces a QALY at a cost that falls below the payer's willingness-to-pay threshold, the price can be justified. If it exceeds that threshold, the product faces formulary exclusion or coverage denial regardless of clinical merit.

Budget impact analysis is the complement to cost-effectiveness analysis and is often more operationally decisive for hospital and payer buyers. While cost-effectiveness asks whether the product is worth it in the aggregate, budget impact asks what it will do to the payer's total spend over the next one to three years when deployed across their patient population. A highly cost-effective product that generates a $50 million budget impact in year one is a serious adoption problem. Payers are managing current-year budgets, not multi-decade actuarial horizons. Budget impact modeling must be part of your pricing justification, not an afterthought.

The distinction between the list price of a pharmaceutical or device and the net price after rebates, discounts, and fees is one of the most important and least understood dynamics in healthcare pricing. Manufacturers often set high list prices to provide negotiating room with pharmacy benefit managers, or PBMs, and payers who demand rebates in exchange for formulary placement. The spread between list and net can exceed 50% for specialty pharmaceuticals. A product priced with a modest list price to signal value may actually perform worse in payer negotiations than a higher-priced product with room to offer competitive rebates.

Outcomes-based contracts — also called value-based agreements or risk-sharing arrangements — are pricing structures where the manufacturer's payment is tied to whether the product delivers its promised clinical outcome in real-world use. In theory, this aligns incentives between manufacturer and payer. In practice, they are operationally difficult because they require agreed-upon outcome definitions, measurement infrastructure, and data-sharing arrangements that most health systems are not equipped to administer. The number of true outcomes-based contracts in the market is far smaller than the volume of press coverage would suggest.

Hospital buyers evaluate product pricing differently from payers, and conflating these two buyers is a common strategic error. A hospital CFO's primary concern is the margin impact of adopting your product. If your product enables a procedure that reimburses well, reduces length of stay, or substitutes for a more expensive alternative already in the supply chain, it can command a premium. If it adds cost to a DRG-paid episode — where the hospital receives a fixed payment for the entire episode regardless of what it spends — the hospital bears the full cost and will negotiate price aggressively or decline to adopt.

Pricing for employer-sponsored health plans, which cover roughly 160 million Americans, follows a different logic again. Self-insured employers pay claims directly and are highly motivated by total cost of care reduction, productivity outcomes, and employee health benefit satisfaction. Point solutions targeting employers — mental health apps, diabetes management platforms, chronic condition programs — are typically priced on a per-member-per-month basis and evaluated against claims cost reduction. The challenge is that claims data lags are long, attribution is contested, and many employers are fatigued by point solutions that create administrative complexity without demonstrable savings.